Hearing loss among patients with multiple sclerosis (PwMS): A systematic review and meta-analysis

Mirmosayyeb, Omid; Naderi, Mohammadjavad; Raeisi, Sina; Ebrahimi, Narges; Ghaffary, Elham Moases; Afshari-Safavi, Alireza; Barzegar, Mahdi; Shaygannejad, Vahid

doi:10.1016/j.msard.2022.103754

Cited by 5 publications

(5 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MS affects approximately 2.5 million people worldwide. Affected people are typically between the ages of 20 and 40 years, and the disease prevalence is three times higher among women than among men [ 100 – 102 ]. Mirzazadeh et al.…”

Section: Jak–stat Inhibitory Effects Of Quercetin On Neurodegenerativ...mentioning

confidence: 99%

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

et al. 2022

View full text Add to dashboard Cite

The Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway is involved in many immunological processes, including cell growth, proliferation, differentiation, apoptosis, and inflammatory responses. Some of these processes can contribute to cancer progression and neurodegeneration. Owing to the complexity of this pathway and its potential crosstalk with alternative pathways, monotherapy as targeted therapy has usually limited long-term efficacy. Currently, the majority of JAK–STAT-targeting drugs are still at preclinical stages. Meanwhile, a variety of plant polyphenols, especially quercetin, exert their inhibitory effects on the JAK–STAT pathway through known and unknown mechanisms. Quercetin has shown prominent inhibitory effects on the JAK–STAT pathway in terms of anti-inflammatory and antitumor activity, as well as control of neurodegenerative diseases. This review discusses the pharmacological effects of quercetin on the JAK–STAT signaling pathway in solid tumors and neurodegenerative diseases.

show abstract

Section: Jak–stat Inhibitory Effects Of Quercetin On Neurodegenerativ...mentioning

confidence: 99%

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Of the 64 SRs included in Briscoe et al [35], 17 met the inclusion criteria for this secondary analysis (see Table 2) [38][39][40][41][42][43][44][45][46][47][48][49][50][51][52]. Of these, seven were published in 2021, and 10 were published in 2022.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…Of the 17 included SRs, 10 considered physiological risk factors for hearing loss [38][39][40][41][42][43][44][45][46][47], four considered environmental risk factors [52][53][54], two considered demographic risk factors [49,50], and one considered behavioral risk factors [48]. Of the 251 primary studies, 248 were observational studies, and three were RCTs.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The occupation was the next most frequently reported data, including at baseline in 81 studies (32.66%) and in the results of 69 studies (27.82%) (see Table 3). All 17 SRs included studies which reported gender and personal characteristics at baseline, and 15 SRs included studies which reported gender and personal characteristics in the analysis of results, although in some reviews the latter was in a small proportion of included studies [38,[41][42][43][44][45][46][47][48][49][50][51][52][53][54]. Studies reporting data on occupation were included in a total of eight SRs [38,42,45,48,49,51,53,54].…”

Section: Observational Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Consideration of health inequity in systematic reviews and primary studies on risk factors for hearing loss

Briscoe,

Shaw,

Nunns

et al. 2024

Cochrane Evidence Synthesis and Methods

View full text Add to dashboard Cite

BackgroundHealth inequities are systematic, avoidable, and unfair differences in health between populations or population subgroups. There is increased recognition of the need for systematic reviews (SRs) to address health inequities, including drawing out findings relevant to low‐ and middle‐income countries (LMICs). The aim of this study was to determine the extent to which SRs on risk factors for hearing loss reported findings associated with health inequities, and the extent to which this data was captured in the primary studies included within these SRs.MethodsWe identified SRs on risk factors for hearing loss from a report on this topic which included a systematic search for relevant SRs. SRs thus identified were inspected for data related to health inequity with reference to PROGRESS‐Plus. We compared how data were reported in SRs versus within primary studies included in the SRs, and the extent to which primary studies from LMICs were represented.ResultsWe included 17 SRs which reported findings on a variety of physiological, behavioral, demographic, and environmental risk factors for hearing loss. There were 296 unique primary studies included in the SRs, of which 251 (81.49%) were successfully retrieved. Data relating to health inequities was reported relatively infrequently in the SRs and mainly focused on gender and age. Data related to health inequities was more frequently reported in primary studies. However, several PROGRESS‐Plus criteria were only reported in a minority of primary studies. Approximately one‐third of primary studies were from LMICs.ConclusionsThere is scope to improve the reporting of data relating to health inequities in primary studies on risk factors for hearing loss. However, SR authors could do more to report health inequities than is currently undertaken, including drawing out findings relevant to LMICs where data are available.

show abstract

“…Multiple sclerosis (MS) is an autoimmune disease, defined by chronic inflammation, demyelination, leading to neurological impairment [118,119] The most common cause of neurologic dysfunction in young adults is MS [120]. Inflammation, demyelination and neuro-axonal injury are renowned features of MS that affect the central nervous system and cause long-term persistent disability [120].…”

Section: Correlation Between Exosome and Multiple Sclerosis (Ms)mentioning

confidence: 99%

Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid

et al. 2022

View full text Add to dashboard Cite

Exosomes, known as a type of extracellular vesicles (EVs), are lipid particles comprising heterogeneous contents such as nucleic acids, proteins, and DNA. These bi-layered particles are naturally released into the extracellular periphery by a variety of cells such as neoplastic cells. Given that exosomes have unique properties, they can be used as vectors and carriers of biological and medicinal particles like drugs for delivering to the desired areas. The proteins and RNAs being encompassed by the circulating exosomes in B-cell malignancies are deemed as the promising sources for diagnostic and prognostic biomarkers, as well as therapeutic agents. Exosomes can also provide a “snapshot” view of the tumor and metastatic landscape at any particular time. Further, clinical research has shown that exosomes are produced by immune cells such as dendritic cells can stimulate the immune system, so these exosomes can be used in antitumor vaccines. Despite the great potential of exosomes in the fields of diagnostic and treatment, further studies are in need for these purposes to reach a convergence notion. This review highlights the applications of exosomes in multiple immune-related diseases, including chronic lymphocytic leukemia, multiple sclerosis, and arthritis rheumatoid, as well as explaining sundry aspects of exosome therapy and the function of exosomes in diagnosing diseases.

show abstract

Hearing loss among patients with multiple sclerosis (PwMS): A systematic review and meta-analysis

Cited by 5 publications

References 64 publications

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

Consideration of health inequity in systematic reviews and primary studies on risk factors for hearing loss

Exosome application in treatment and diagnosis of B-cell disorders: leukemias, multiple sclerosis, and arthritis rheumatoid

Contact Info

Product

Resources

About